The firms previously collaborated in 2018 to support multicenter clinical trials requiring PET for eligibility and drug efficacy evaluation. In an expanded partnership, the companies will now team up to expedite clinical trials and drug discovery in China for targets such as amyloid, tau, and others, according to Clario and XingImaging.